R
Ross C. Donehower
Researcher at Johns Hopkins University
Publications - 233
Citations - 32588
Ross C. Donehower is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Pharmacokinetics & Chemotherapy. The author has an hindex of 72, co-authored 229 publications receiving 28457 citations. Previous affiliations of Ross C. Donehower include Johns Hopkins University School of Medicine & National Institutes of Health.
Papers
More filters
Journal Article
A Phase I and Pharmacologic Evaluation of the DNA Intercalator CI-958 in Patients with Advanced Solid Tumors
E. Claire Dees,Lloyd R. Whitfield,William Grove,Sue Rummel,Louise B. Grochow,Ross C. Donehower +5 more
TL;DR: Neutropenia and hepatorenal toxicity were the dose-limiting toxicities, which defined the maximum tolerated dose of CI-958 to be 875 mg/m2 when given as a 2-h infusion every 21 days.
Journal ArticleDOI
A phase I study of menogaril in patients with advanced cancer.
TL;DR: Menogaril (7-con-O-methylnogarol) is a semisynthetic anthracycline analogue of nogalamycin that has shown good activity against a variety of experimental tumor systems as well as decreased cardiac toxicity when compared with doxorubicin in preclinical studies.
Journal Article
Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrations.
Eric K. Rowinsky,Barbara A. Conley,Richard J. Jones,Jerry L. Spivak,Michael Auerbach,Ross C. Donehower +5 more
TL;DR: The induction of cytopenias and lack of significant clinical improvements suggest that HMBA is cytotoxic and will not be useful alone as a differentiating agent on this schedule of administration in the treatment of MDS.
Journal ArticleDOI
Factors affecting topotecan sensitivity in human leukemia samples
Scott H. Kaufmann,Steven D. Gore,Louis Letendre,Phyllis A. Svingen,Timothy Kottke,Christopher A. Buckwalter,Richard J. Jones,Louise B. Grochow,Philip J. Burke,Ross C. Donehower,Eric K. Rowinsky +10 more
Journal ArticleDOI
Clinical Pharmacology of Oral and Iv N-Methylformamide: A Pharmacologic Basis for Lack of Clinical Antineoplastic Activity
Eric K. Rowinsky,Dennis A. Noe,Douglas W. Orr,Louise B. Grochow,David S. Ettinger,Ross C. Donehower +5 more
TL;DR: Pharmacodynamic associations were observed between the magnitude of the area under the plasma disappearance curves and hepatotoxicity, the dose-limiting toxic effect of iv NMF, and the symptom complex of nausea, vomiting, and malaise, which precluded dose escalation of oral NMF.